TOP TEN perturbations for 38621_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38621_at
Selected probe(set): 215537_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38621_at (215537_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):2.7969656
Number of Samples:2 / 3
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

G-CSF study 1 / untreated leukocyte sample

Relative Expression (log2-ratio):2.59906
Number of Samples:5 / 5
Experimental G-CSF study 1
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained after administration of granulocyte-colony stimulating factor (G-CSF; 10μg/kg/day for five days). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.
Control untreated leukocyte sample
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained before administration of granulocyte-colony stimulating factor (G-CSF). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.

brain tumor study 1 (medulloblastoma) / normal brain tissue

Relative Expression (log2-ratio):2.4199219
Number of Samples:22 / 12
Experimental brain tumor study 1 (medulloblastoma)
Primary tumor tissue sample from the brain of patients with medulloblastoma.
Control normal brain tissue
Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors.

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):-2.3694468
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

medulloblastoma study 1 / non-tumor brain tissue

Relative Expression (log2-ratio):2.3495893
Number of Samples:17 / 9
Experimental medulloblastoma study 1
Primary tumor tissue sample from the infratentorial brain of pediatric patients with classical medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

septic shock study 3 (D1; survivor) / normal blood sample

Relative Expression (log2-ratio):2.2922382
Number of Samples:34 / 22
Experimental septic shock study 3 (D1; survivor)
Blood samples from patients (survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):2.2661915
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.2279263
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

septic shock study 3 (D2; survivor) / normal blood sample

Relative Expression (log2-ratio):2.174778
Number of Samples:12 / 22
Experimental septic shock study 3 (D2; survivor)
Blood samples from patients (survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):2.1738806
Number of Samples:3 / 21
Experimental adefovir study 1 (50uM)
HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.